Literature DB >> 9322899

Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence.

E Orlandi1, M Lazzarino, E Brusamolino, M Paulli, C Astori, U Magrini, C Bernasconi.   

Abstract

We evaluated the presenting clinical characteristics and outcome of 68 patients with nodular lymphocyte predominance Hodgkin's disease (NLP-HD), in order to delineate the pattern of evolution of the disease. The male to female ratio was 46/22 and median age 35 yrs (range, 14-86). Eight patients had a history of benign hyperplasia on lymph node biopsies performed 6 to 36 months before the diagnosis of NLP-HD. Early stage disease accounted for 75% of cases. One patient had a coexistent non-Hodgkin's lymphoma (NHL). Treatment was as follows: radiotherapy in 26, chemotherapy in 23, combined modality in 19. CR rate was 93% (63/68). 18 patients relapsed as HD and 5 developed NHL. The cumulative risk of NHL was 9% at 10 yrs. During remission, 4 patients had 5 episodes of follicular hyperplasia histologically documented. Overall survival rate was 71% at 10 yrs and and 63% at 15 yrs. Freedom from progression (FFP) declined from 67% at 5 yrs to 45% at 10 yrs, because of late relapses. Localized disease predicted for a better FFP (p = 0.01), but was not associated with a reduced risk of recurrence over time. NLP-HD is characterized by an indolent course with a constant pattern of relapse over time, also in patients with early stage disease at diagnosis. In addition to relapse as NLP-HD, patients may evolve into a NHL or develop benign lymph nodal hyperplasia. Careful long-term follow up is needed for these patients.

Entities:  

Mesh:

Year:  1997        PMID: 9322899     DOI: 10.3109/10428199709051786

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Sven Borchmann; Erel Joffe; Craig H Moskowitz; Andrew D Zelenetz; Ariela Noy; Carol S Portlock; John F Gerecitano; Connie L Batlevi; Philip C Caron; Pamela Drullinsky; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Colette N Owens; M Lia Palomba; Anas Younes; David J Straus
Journal:  Blood       Date:  2019-02-15       Impact factor: 22.113

Review 2.  Lymphocyte predominant Hodgkin's disease.

Authors:  Bradley C Ekstrand; Sandra J Horning
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

3.  Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

4.  Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Jean François Grellier; Laetitia Vercellino; Thierry Leblanc; Pascal Merlet; Catherine Thieblemont; Pierre Weinmann; Marie-Elisabeth Toubert; Nathalie Berenger; Josette Brière; Pauline Brice
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-26       Impact factor: 9.236

5.  Open questions in the management of nodular lymphocyte predominant hodgkin lymphoma.

Authors:  Marguerite Tyran; Laurence Gonzague; Reda Bouabdallah; Michel Resbeut
Journal:  Case Rep Hematol       Date:  2014-02-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.